{
    "eid": "2-s2.0-85167904304",
    "title": "Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy",
    "cover-date": "2023-07-11",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Kitsada Wudhikarn",
        "Ana Alarcon Tomas",
        "Jessica R. Flynn",
        "Sean M. Devlin",
        "Jamie Brower",
        "Veronika Bachanova",
        "Loretta J. Nastoupil",
        "Joseph P. McGuirk",
        "Richard T. Maziarz",
        "Olalekan O. Oluwole",
        "Stephen J. Schuster",
        "David L. Porter",
        "Michael R. Bishop",
        "Peter A. Riedell",
        "Miguel Angel Perales"
    ],
    "citedby-count": 5,
    "ref-count": 21,
    "ref-list": [
        "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma",
        "Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma",
        "Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study",
        "Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy",
        "High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma",
        "The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells",
        "Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma",
        "Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia",
        "Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion",
        "Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas",
        "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification",
        "ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells",
        "Enhanced responses to tumor immunization following total body irradiation are time-dependent",
        "Chimeric antigen receptor T cell therapy: a comprehensive review of clinical efficacy, toxicity, and best practices for outpatient administration",
        "Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma",
        "Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium",
        "Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy",
        "Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma",
        "Role of CD19 chimeric antigen receptor T cells in second-line large B cell lymphoma: lessons from phase 3 trials. An expert panel opinion from the American Society for Transplantation and Cellular Therapy",
        "Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma",
        "Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era"
    ],
    "affiliation": [
        {
            "affiliation-city": "New York",
            "@id": "60009343",
            "affilname": "Memorial Sloan-Kettering Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009343",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Madrid",
            "@id": "60033237",
            "affilname": "Hospital General Universitario Gregorio Mara\u00f1\u00f3n",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60033237",
            "affiliation-country": "Spain"
        },
        {
            "affiliation-city": "Minneapolis",
            "@id": "60029445",
            "affilname": "University of Minnesota Twin Cities",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029445",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Chicago",
            "@id": "60029278",
            "affilname": "The University of Chicago",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029278",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Nashville",
            "@id": "60024890",
            "affilname": "Vanderbilt-Ingram Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60024890",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Philadelphia",
            "@id": "60023009",
            "affilname": "Penn Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60023009",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Portland",
            "@id": "60016733",
            "affilname": "Oregon Health &amp; Science University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016733",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Lawrence",
            "@id": "60015457",
            "affilname": "University of Kansas",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015457",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Houston",
            "@id": "60015023",
            "affilname": "The University of Texas MD Anderson Cancer Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015023",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "New York",
            "@id": "60007997",
            "affilname": "Weill Cornell Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007997",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "National Institutes of Health",
        "National Cancer Institute",
        "National Center for Advancing Translational Sciences",
        "Novartis Pharmaceuticals, Inc."
    ]
}